Skip to main content

Table 2 Occurrence of DLTs

From: Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data

AZD3514 dose

Number eligible

Number of DLTs

Proportion that experienced a DLT

Eligible patients experiencing DLT (DLT = D, No DLT = blank)

1st

2nd

3rd

4th

5th

6th

250 mg QD

6

0

0 %

      

500 mg QD

6

0

0 %

      

1000 mg QD

6

1

16.7 %

D

     

1000 mg BID

6

3

50 %

 

D

 

D

D

 

2000 mg BID

4

4

100 %

D

D

D

D

-

-